Indication
Osteoporosis in male patient
Osteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures. Read more about Osteoporosis in male patient
63 drugs 52 manufacturers
Drugs that treat it
Common Osteoporosis in male patient therapies.
BILDYOS (denosumab-nxxp)
OSPOMYV (denosumab-dssb)
ALENDRONATE SODIUM
TERIPARATIDE
ENOBY (denosumab-qbde)
TERIPARATIDE
BOSAYA (denosumab-kyqq)
OSVYRTI (denosumab-desu)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonOsteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures.
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy.
Clinically, it is diagnosed by a low-trauma fragility fracture or a bone mineral density T-score of -2.5 or lower at the spine or hip, carrying significant morbidity and higher post-fracture mortality rates compared to female counterparts.
- nih.gov
Osteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures
- nih.gov
Osteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures
- nih.gov
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy Clinically, it is diagnosed by a low-trauma fragility fracture or a bone mineral density T-score of −2.5 or lower at the spine or hip, carrying...
- nih.gov
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy
- nih.gov
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy
- oup.com
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy Clinically, it is diagnosed by a low-trauma fragility fracture or a bone mineral density T-score of −2.5 or lower at the spine or hip, carrying...
- nih.gov
Clinically, it is diagnosed by a low-trauma fragility fracture or a bone mineral density T-score of −2.5 or lower at the spine or hip, carrying significant morbidity and higher post-fracture mortality rates compared to female counterparts
Personalize your experience
Follow Osteoporosis in male patient and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.